BMY
Bristol-Myers Squibb Company
Bristol-Myers Squibb Company historical holders
total: 20
Muhlenkamp & Co Bristol-Myers Squibb Company transactions over time
- Total transactions:
- 35
- New positions:
- 2
- Sold out:
- 2
- Added:
- 19
- Reduced:
- 12
- Held since:
- 2019 Q4
- Held for:
- 16 quarters
- Latest activity:
- 2024 Q2
Ronald Muhlenkamp has been an institutional investor in Bristol-Myers Squibb Company (BMY) since 2014 Q1. According to 2026 Q1 report, Ronald Muhlenkamp doesn't hold any shares. The fund/company first acquired BMY in 2014 Q1, initially purchasing 212,015 shares. Ronald Muhlenkamp later completely sold out the position and reinvested in BMY again in 2019 Q4. Since the initial investment, Muhlenkamp & Co has made 34 more transactions in this position.
When did Ronald Muhlenkamp exit their BMY position?
Ronald Muhlenkamp no longer holds Bristol-Myers Squibb Company (BMY). They sold off their entire position in 2024 Q2, closing out an investment that began in 2014 Q1.
When did Ronald Muhlenkamp first invest in BMY?
Ronald Muhlenkamp first invested in Bristol-Myers Squibb Company (BMY) in 2014 Q1 at the reported quarter-end price of $51.95 per share, acquiring 212,015 shares in their initial purchase.
What is Ronald Muhlenkamp's average cost basis for BMY?
Based on historical transaction data, Ronald Muhlenkamp's estimated cost basis for Bristol-Myers Squibb Company (BMY) is approximately $63.91 per share. This represents their average reported price* across all buy transactions.
Has Ronald Muhlenkamp reinvested in BMY after selling?
Yes, Ronald Muhlenkamp has shown renewed interest in Bristol-Myers Squibb Company (BMY). After completely selling their position, they reinitiated an investment in 2019 Q4, demonstrating continued conviction in this ticker.
Estimated cost basis*
- Weighted AVG buy price:
- $63.90
- Weighted AVG sell price:
- $54.24
BMY transactions history by Muhlenkamp & Co
35 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2024 Q2
|
0.00%
|
0
|
$54.23
|
|
-100% (-135,045)
|
-2.13%
|
|
2024 Q1
|
2.13%
|
135,045
|
$54.23
|
$7,323,490
|
+2.49% (+3,285)
|
+0.05%
|
|
2023 Q4
|
2.21%
|
131,760
|
$51.31
|
$6,760,606
|
+1.56% (+2,028)
|
+0.03%
|
|
2023 Q3
|
2.60%
|
129,732
|
$58.04
|
$7,529,645
|
+0.13% (+163)
|
+0%
|
|
2023 Q2
|
2.94%
|
129,569
|
$63.95
|
$8,285,938
|
+0.48% (+619)
|
+0.01%
|
|
2022 Q4
|
3.93%
|
128,950
|
$71.95
|
$9,277,953
|
+0.15% (+197)
|
+0.01%
|
|
2022 Q3
|
4.09%
|
128,753
|
$71.09
|
$9,153,000
|
+0.94% (+1,197)
|
+0.04%
|
|
2022 Q2
|
4.60%
|
127,556
|
$77.00
|
$9,822,000
|
+0.51% (+650)
|
+0.02%
|
|
2022 Q1
|
3.23%
|
126,906
|
$73.03
|
$9,268,000
|
+0.73% (+919)
|
+0.02%
|
|
2021 Q4
|
2.74%
|
125,987
|
$62.35
|
$7,855,000
|
+0.45% (+568)
|
+0.01%
|
|
2021 Q3
|
2.85%
|
$59.17
|
-0.16% (-204)
|
|||
|
2021 Q2
|
3.08%
|
$66.82
|
+0.16% (+204)
|
|||
|
2021 Q1
|
3.20%
|
$68.96
|
+0.22% (+281)
|
|||
|
2020 Q4
|
3.12%
|
$62.03
|
+0.73% (+913)
|
|||
|
2020 Q3
|
3.88%
|
$60.29
|
+0.77% (+952)
|
|||
|
2020 Q2
|
3.88%
|
$58.80
|
+0.04% (+50)
|
|||
|
2019 Q4
|
3.46%
|
$64.19
|
new
|
|||
|
2018 Q2
|
0.00%
|
$63.25
|
-100% (-178,436)
|
|||
|
2018 Q1
|
4.12%
|
$63.25
|
+2.21% (+3,861)
|
|||
|
2017 Q4
|
3.30%
|
$61.28
|
-1.46% (-2,594)
|
|||
|
2017 Q3
|
3.75%
|
$63.74
|
-0.45% (-805)
|
|||
|
2017 Q2
|
3.25%
|
$55.72
|
-0.13% (-227)
|
|||
|
2017 Q1
|
3.14%
|
$54.38
|
-0.42% (-760)
|
|||
|
2016 Q4
|
3.49%
|
$58.44
|
-0.75% (-1,355)
|
|||
|
2016 Q3
|
3.72%
|
$53.92
|
-0.56% (-1,024)
|
|||
|
2016 Q2
|
5.25%
|
$73.55
|
-14.54% (-30,860)
|
|||
|
2016 Q1
|
5.58%
|
$63.88
|
+0.21% (+445)
|
|||
|
2015 Q4
|
4.59%
|
$68.79
|
+0.00% (+5)
|
|||
|
2015 Q3
|
3.85%
|
$59.20
|
+0.06% (+130)
|
|||
|
2015 Q2
|
3.17%
|
$66.54
|
-0.26% (-550)
|
|||
|
2015 Q1
|
2.89%
|
$64.50
|
-0.06% (-120)
|
|||
|
2014 Q4
|
2.53%
|
$59.03
|
-0.09% (-195)
|
|||
|
2014 Q3
|
1.99%
|
$51.18
|
-0.13% (-285)
|
|||
|
2014 Q2
|
1.84%
|
$48.51
|
+0.36% (+755)
|
|||
|
2014 Q1
|
1.95%
|
$51.95
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.